Streetbeat News

Earnings

IART

IRWD

PACB

The article highlights the top 3 oversold health care stocks with potential for significant gains in March, based on their low RSI values. Pacific Biosciences of California, Ironwood Pharmaceuticals, and Integra LifeSciences are identified as undervalued, presenting a buying opportunity. Recent financial results and stock performance are discussed for each company.

Portfolio Pulse from Avi Kapoor

March 07, 2024 | 12:18 pm

BITF

Bitfarms (NASDAQ:BITF) reported Q4 sales of $46.24M, surpassing the analyst consensus estimate of $43.08M by 7.34% and marking a 71.02% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:17 pm

FHTX

Foghorn Therapeutics reported a significant increase in its FY23 collaboration revenue, reaching $34.2 million compared to $19.2 million in the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:16 pm

SUP

Superior Industries Intl's shares dropped following the announcement of their Q4 financial results, which fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:15 pm

BIG

Big Lots reported mixed Q4 results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:15 pm

TSLA

Tesla, Inc. (NASDAQ:TSLA) is on track to decline for the fourth consecutive day amid concerns over a shutdown at its Giga Berlin factory affecting Q1 deliveries. The shutdown, caused by suspected arson leading to a power outage, may result in a loss of 9,000 units of production. Despite this, Future Fund's Gary Black maintains his Q1 delivery estimate at 425,000 units, below the analyst consensus of 474,000 units. Tesla's stock has been trading lower, with a 2.32% drop on Wednesday and a further 1.42% decrease in premarket trading on Thursday.

Portfolio Pulse from Shanthi Rexaline

March 07, 2024 | 12:14 pm

OSPN

OneSpan shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:12 pm

HOWL

Werewolf Therapeutics (NASDAQ:HOWL) reported Q4 earnings with EPS of $(0.33), beating estimates by 23.26% but missed sales estimates with $1.50M, a 22.63% miss and a 79.39% decrease from last year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:12 pm

HNST

The Honest Company's shares surged following the announcement of their Q4 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:11 pm

YEXT

Yext shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:11 pm